ELTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Elicio Therapeutics Inc (ELTX) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock lacks immediate positive catalysts, has weak financial performance, and no significant trading signals. While analysts have a Buy rating with a raised price target, the company's fundamentals and technical indicators do not currently support a strong entry point.
The MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 44.686, and moving averages are converging, showing no clear trend. The stock is trading near its pivot level of 10.857, with support at 10.059 and resistance at 11.655.
Analysts have raised the price target to $17, citing potential commercial opportunities for ELI-002 in mKRAS-driven cancers and additional pipeline value.
Weak financial performance with declining net income (-44.89% YoY) and EPS (-51.46% YoY). No significant news or trading activity from hedge funds, insiders, or Congress. Technical indicators show no clear bullish trend.
In Q4 2025, the company reported no revenue growth, a net income decline of -44.89% YoY, and an EPS drop of -51.46% YoY. Gross margin remains at 0.
Analysts from H.C. Wainwright and Rodman & Renshaw have Buy ratings with a $17 price target, reflecting optimism about ELI-002 and the company's pipeline.
